Restricted accessResearch articleFirst published online 2023-12-06
Association of COVID-19 with Risk and Progression of Alzheimer’s Disease: Non-Overlapping Two-Sample Mendelian Randomization Analysis of 2.6 Million Subjects
Epidemiological studies showed that COVID-19 increases risk of Alzheimer’s disease (AD). However, it remains unknown if there is a potential genetic predispositional effect.
Objective:
To examine potential effects of genetic susceptibility of COVID-19 on the risk and progression of AD, we performed a non-overlapping 2-sample Mendelian randomization (MR) study using summary statistics from genome-wide association studies (GWAS).
Methods:
Two-sample Mendelian randomization (MR) analysis of over 2.6 million subjects was used to examine whether genetic susceptibility of COVID-19 is not associated with the risk of AD, cortical amyloid burden, hippocampal volume, or AD progression score. Additionally, a validation analysis was performed on a combined sample size of 536,190 participants.
Results:
We show that the AD risk was not associated with genetic susceptibility of COVID-19 risk (OR = 0.98, 95% CI 0.81–1.19) and COVID-19 severity (COVID-19 hospitalization: OR = 0.98, 95% CI 0.9–1.07, and critical COVID-19: OR = 0.98, 95% CI 0.92–1.03). Genetic predisposition to COVID-19 is not associated with AD progression as measured by hippocampal volume, cortical amyloid beta load, and AD progression score. These findings were replicated in a set of 536,190 participants. Consistent results were obtained across models based on different GWAS summary statistics, MR estimators and COVID-19 definitions.
Conclusions:
Our findings indicated that the genetic susceptibility of COVID-19 is not associated with the risk and progression of AD.
MarshallM (2021) COVID and the brain: Researchers zero in on how damage occurs. Nature595, 484–485.
5.
ReikenS, SittenfeldL, DridiH, LiuY, LiuX, Marks DementiaAR (2022) Alzheimer’s-like signaling in brains of COVID-19 patients. Alzheimers Dement18, 955–965.
6.
SulzerD, AntoniniA, LetaV, NordvigA, SmeyneRJ, GoldmanJE, Al-DalahmahO, ZeccaL, SetteA, BubaccoLJ, MeucciO, MoroE, HarmsAS, XuY, FahnS, ChaudhuriKR (2020) COVID-19 and possible links with Parkinson’s disease and parkinsonism: From bench to bedside. NPJ Parkinsons Dis6, 18.
7.
MeerD, Pinzón-EspinosaJ, LinBD, TijdinkJK, VinkersCH, GuloksuzS, LuykxJJ (2020) Associations between psychiatric disorders, COVID-19 testing probability and COVID-19 testing results: Findings from a population-based study. , e, BJPsych Open6, 87.
8.
LeeSW, YangJM, MoonSY, YooIK, HaEK, KimSY, ParkUM, ChoiS, LeeS-H, AhnYM, KimJM, KohHY, YonDK (2020) Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: A nationwide cohort study. Lancet Psychiatry7, 1025–1031.
9.
ZarifkarP, PeinkhoferC, BenrosME, KondziellaD (2022) Frequency of neurological diseases after COVID-19, influenza A/B and bacterial pneumonia. Front Neurol13, 1276.
10.
WangL, DavisPB, VolkowND, BergerNA, KaelberDC, XuR (2022) Association of COVID-19 with new-onset Alzheimer’s disease. J Alzheimers Dis89, 411–414.
11.
SeyedAlinaghiS, MehrtakM, MohsseniPourM, MirzapourP, BarzegaryA, HabibiP, Moradmand-BadieB, AfsahiAM, KarimiA, HeydariM, MehraeenE, DadrasO, SabatierJM, VoltarelliF (2021) Genetic susceptibility of COVID-19: A systematic review of current evidence. Eur J Med Res26, 46.
12.
AsgariS, PousazLA (2021) Human genetic variants identified that affect COVID susceptibility and severity. Nature600, 390–391.
13.
ShinJJ, FanW, Par-YoungJ, PiecychnaM, LengL, Israni-WingerK, QingH, GuJ, ZhaoH, SchulzWL, UnluS, KusterJ, YoungG, LiuJ, KoAI, GarciaAB, SaulerM, WisnewskiAV, YoungL, OrduñaA, WangA, OcskayK, Garcia-BlesaA, HegyiP, ArmstrongME, MitchellPD, BernardoD, GaramiA, KangI, BucalaR (2023) MIF is a common genetic determinant of COVID-19 symptomatic infection and severity. QJM116, 205–212.
ZhuX, LiX, XuR, WangT (2021) An iterative approach to detect pleiotropy and perform Mendelian Randomization analysis using GWAS summary statistics. Bioinformatics37, 1390–1400.
16.
ZhuX (2021) Mendelian randomization and pleiotropy analysis. Quant Biol9, 122–132.
17.
BaranovaA, CaoH, ZhangF (2023) Causal effect of COVID-19 on Alzheimer’s disease: A Mendelian randomization study, J Med Virol95, e28107.
18.
LiC, LiuJ, LinJ, ShangH (2022) COVID-19 and risk of neurodegenerative disorders: A Mendelian randomization study. Transl Psychiatry12, 283.
19.
ZhangH, ZhouZ (2022) COVID-19 and the risk of Alzheimer’s disease, amyotrophic lateral sclerosis, and multiple sclerosis. Ann Clin Transl Neurol9, 1953–1961.
20.
SunD, WangR, ShiZ, ChenH, ZhouH (2023) Causal relationship of COVID-19 on Alzheimer’s disease: An updated Mendelian randomization study. Neurol Sci44, 1–2.
21.
TirozziA, SantonastasoF, de Gaetano G, IacovielloL, GialluisiA (2022) Does COVID-19 increase the risk of neuropsychiatric sequelae? Evidence from a mendelian randomization approach. World J Psychiatry12, 536.
22.
BurgessS, DaviesNM, ThompsonSG (2016) Bias due to participant overlap in two-sample Mendelian randomization. Genet Epidemiol40, 597–608.
23.
SadreevII, ElsworthBL, MitchellRE, PaternosterL, SandersonE, DaviesNM, MillardLA, SmithGD, HaycockPC, BowdenJ, GauntTR, HemaniG (2021) Navigating sample overlap, winner’s curse and weak instrument bias in Mendelian randomization studies using the UK Biobank. MedRxiv, doi:10.1101/2021.06.28.21259622.
24.
QiuS, HuY, ChengL (2022) A genome-wide cross-trait analysis highlights the shared genetic structure between COVID-19 and Alzheimer’s disease. , e1-e, J Infect84, e1–e2.
25.
DingP, XuR (2023) Causal association of COVID-19 with brain structure changes: Findings from a non-overlapping 2-sample Mendelian randomization study. MedRxiv, doi:10.1101/2023.07.16.23292735.
26.
The COVID-19 Host Genetics Initiative
(2020) The COVID-19 host genetics initiative, a global initiative to elucidate the role of host genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. Eur J Hum Genet28, 715–718.
KunkleBW, Grenier-BoleyB, SimsR, BisJC, DamotteV, NajAC, BolandA, VronskayaM, Van Der Lee SJ, Amlie-WolfA, et al. (2019) Genetic meta-analysis of diagnosed Alzheimer’s disease identifies new risk loci and implicates Aβ, tau, immunity and lipid processing. Nat Genet51, 414–430.
HemaniG, TillingK, Davey Smith G (2017) Orienting the causal relationship between imprecisely measured traits using GWAS summary data, PLoS Genet13, e1007081.
32.
VerbanckM, ChenCY, NealeB, DoR (2018) Detection of widespread horizontal pleiotropy in causal relationships inferred from Mendelian randomization between complex traits and diseases. Nat Genet50, 693–698.
33.
BurgessS, ButterworthA, ThompsonSG (2013) Mendelian randomization analysis with multiple genetic variants using summarized data. Genet Epidemiol37, 658–665.
34.
BowdenJ, Davey Smith G, HaycockPC, Burgess GeSJ (2016) Consistent estimation in Mendelian randomization with some invalid instruments using a weighted median estimator. Genet Epidemiol40, 304–314.
35.
BowdenJ, Davey Smith G, BurgessS (2015) Mendelian randomization with invalid instruments: Effect estimation and bias detection through Egger regression. Int J Epidemiol44, 512–525.
36.
BowdenJ, Del Greco M F, MinelliC, ZhaoQ, LawlorDA, SheehanNA, ThompsonJ, Davey Smith G (2019) Improving the accuracy of two-sample summary-data Mendelian randomization: Moving beyond the NOME assumption. Int J Epidemiol48, 728–742.
37.
BowdenJ, Del Greco M F, MinelliC, Davey Smith G, SheehanN, ThompsonJ (2017) A framework for the investigation of pleiotropy in two-sample summary data Mendelian randomization. Stat Med36, 1783–1802.
38.
BowdenJ, HolmesMV (2019) Meta-analysis and Mendelian randomization: A review. Res Synth Methods10, 486–496.
39.
HemaniG, BowdenJ, Davey Smith G (2018) Evaluating the potential role of pleiotropy in Mendelian randomization studies. , , Hum Mol Genet27, R195–R208.
40.
BrumptonB, SandersonE, HeilbronK, HartwigFP, HarrisonS, VieGÅ, ChoY, HoweLD, HughesA, BoomsmaDI, HavdahlA, HopperJ, NealeM, NivardMG, PedersenNL, ReynoldsCA, Tucker-DrobEM, GrotzingerA, HoweL, MorrisT, LiS, The Within-family Consortium, The 23andMe Research Team, AutonA, WindmeijerF, ChenWM, Bjørngaard JH, HveemK, WillerC, EvansDM, KaprioJ, Davey Smith G, Olav ÅsvoldB, HemaniG, DaviesNM (2020) Avoiding dynastic, assortative mating, and population stratification biases in Mendelian randomization through within-family analyses. Nat Commun11, 3519.
41.
LawlorDA, HarbordRM, SterneJA, TimpsonN, Davey Smith G (2008) Mendelian randomization: Using genes as instruments for making causal inferences in epidemiology. Stat Med27, 1133–1163.
42.
BurgessS, SmallDS, ThompsonSG (2017) A review of instrumental variable estimators for Mendelian randomization. Stat Methods Med Res26, 2333–2355.
43.
GordonMN, HenekaMT, Le PageLM, LimbergerC, MorganD, TennerAJ, TerrandoN, WilletteAA, WilletteSA (2022) Impact of COVID-19 on the onset and progression of Alzheimer’s disease and related dementias: A roadmap for future research. Alzheimers Dement18, 1038–1046.
44.
KernerG, Quintana-MurciL (2022) The genetic and evolutionary determinants of COVID-19 susceptibility. Eur J Hum Genet30, 915–921.
45.
GaoS, HendrieHC, HallKS, HuiS (1998) The relationships between age, sex, and the incidence of dementia and Alzheimer disease: A meta-analysis. JAMA Psychiatry55, 809–815.
ThomasLE, BonowRO, PencinaMJ (2020) Understanding observational treatment comparisons in the setting of coronavirus disease 2019 (COVID-19). JAMA Cardiol5, 988–990.
51.
CostaBAD, SilvaL, MendesM, KarmannÍ, CamposB, NogueiraM, BatistaR, CendesF, YasudaC (2023) Anxiety And depression are associated with limbic atrophy and severe disruption of brain functional connectivity after mild COVID-19 onfection (S21.007), Neurology100:(17 Suppl 2). doi: 10.1212/WNL.0000000000202252.
52.
DouaudG, LeeS, Alfaro-AlmagroF, ArthoferC, WangC, McCarthyP, LangeF, AnderssonJL, GriffantiL, DuffE, JbabdiS, TaschlerB, KeatingP, WinklerAM, CollinsR, MatthewsPM, AllenN, MillerKL, NicholsTE, SmithSM (2022) SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature604, 697–707.
